TGFB1 and myelodysplastic syndrome: The therapeutic landscape for LR-MDS has expanded considerably over the past two decades, with treatment approaches ranging from supportive care and erythropoiesis-stimulating agents to immunomodulatory drugs, erythrocyte maturation agents (TGF-β inhibitors), and telomerase inhibitors (Figure 2).